Decentralized clinical trials (DCTs) are not a recent invention, but their adoption has accelerated as logistical complexity, geographic dispersion, and patient burden have come under scrutiny. The shift began long before the pandemic, but COVID-19 created a clear breakpoint as by 2020 remote consent, home visits, and digital monitoring moved …
We use cookies to personalise content and to analyse our traffic.
You consent to our cookies if you continue to use our website. Read more details in our
cookies policy.
